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Abstract
Background: Expression microarray analyses of epithelial ovarian cancer (EOC) cell lines may be exploited to elucidate genetic
and epigenetic events important in this disease. A possible variable is the influence of growth conditions on discerning candidates.
The present study examined the influence of growth conditions on the expression of chromosome 3 genes in the tumorigenic
EOC cell lines, OV-90, TOV-21G and TOV-112D using Affymetrix GeneChip® HG-U133A expression microarray analysis.
Methods: Chromosome 3 gene expression profiles (n = 1147 probe sets, representing 735 genes) were extracted from U133A
expression microarray analyses of the EOC cell lines OV-90, TOV-21G and TOV-112D that were grown as monolayers,
spheroids or nude mouse xenografts and monolayers derived from these tumors. Hierarchical cluster analysis was performed
to compare chromosome 3 transcriptome patterns of each growth condition. Differentially expressed genes were identified and
characterized by two-way comparative analyses of fold-differences in gene expression between monolayer cultures and each of
the other growth conditions, and between the maximum and minimum values of expression of all growth conditions for each
EOC cell line.
Results: An overall high degree of similarity (> 90%) in gene expression was observed when expression values of alternative
growth conditions were compared within each EOC cell line group. Two-way comparative analysis of each EOC cell line grown
in an alternative condition relative to the monolayer culture showed that overall less than 15% of probe sets exhibited at least
a 3-fold difference in expression profile. Less than 23% of probe sets exhibited greater than 3-fold differences in gene expression
in comparisons of the maximum and minimum value of expression of all growth conditions within each EOC cell line group. The
majority of these differences were less than 5-fold. There were 17 genes in common which were differentially expressed in all
EOC cell lines. However, the patterns of expression of these genes were not necessarily the same for each growth condition
when one cell line was compared with another.
Conclusion: The various alternative in vivo and in vitro growth conditions of tumorigenic EOC cell lines appeared to modestly
influence the global chromosome 3 transcriptome supporting the notion that the in vitro cell line models are a viable option for
testing gene candidates.
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Background
The molecular genetic analysis of ovarian cancer has been
facilitated by the establishment and characterization of
spontaneously immortalized epithelial ovarian cancer
(EOC) cell lines that have been derived from malignant
cells by long-term growth in cell culture [1]. In our labo-
ratory, we have studied the properties of three EOC cell
lines derived from malignant ovarian tumors (TOV-21G
and TOV112D) and ascites (OV-90) [2,3]. These EOC cell
lines were derived from patient samples prior to chemo-
therapy. They have been extensively characterized and
shown to exhibit many of molecular genetic features,
cytogenetic anomalies, and somatic mutations in tumor
suppressor genes frequently associated with malignant
ovarian cancers [2-4]. An attractive feature of these EOC
cell lines is that they develop tumors at subcutaneous and
intraperitoneal sites in nude mouse xenograft models [2].
The phenotypes of the EOC cell lines are also reflected in
global analyses of gene expression using large-scale gene
expression microarrays analyses where the differentially
expressed genes have been shown to overlap with those
observed independently in the molecular analyses of
ovarian cancers [5-11]. The application of various growth
conditions to capture the full spectrum of the disease
along with large-scale gene expression analyses could be
important in our understanding of the biological and
genetic factors that influence the phenotypic characteris-
tics of the disease [1,12].
A possible variable in the application of EOC cell line
models is the influence of growth conditions on discern-
ing and then characterizing gene candidates which ini-
tially exhibit differential gene expression in in vitro EOC
cell line models. Recently, our group has reported on glo-
bal differences in gene expression between EOC cell lines
that were cultured as monolayers, spheroids, or nude
mouse xenografts suggesting that microenviroment could
impact the transcriptome [13]. To further assess the varia-
bility of gene expression of EOC cell lines propagated in
different contexts, we have extracted chromosome 3 gene
expression profiles from the Affymetrix expression micro-
array data from three tumorigenic EOC cell lines, TOV-
21G, TOV-112D and OV-90, that have been propagated as
monolayers, spheroids or nude mouse xenografts, and
monolayers derived from these xenografts [13]. We have
focused our analysis on the chromosome 3 gene expres-
sion because of our interest in elucidating genes located
on this chromosome in ovarian cancer and the use of
these well established EOC cell lines as models to both
identify and characterize chromosome 3 gene candidates
potentially important in this disease [7,8,14,15]. These
EOC cell lines were derived from ovarian cancer samples
from chemotherapy naïve patients and have been shown
to exhibit unique karyotypic abnormalities [2]. Both OV-
90 and TOV-112D exhibit complex karyotypic anomalies
consistent with those typically seen in the majority of
EOCs, whereas TOV-21G exhibited an atypical diploid
karyotype with trisomy 10 as the only gross abnormality
[2,16]. Karyotype analysis has demonstrated evidence of
an unique chromosome 3 abnormality in OV-90 com-
prised of a chromosome 22 derived homogeneously stain-
ing region replacing the 3p arm but not affecting the 3q
arm [2,5]. In particular, OV-90 has emerged as an interest-
ing in vitro model with the potential for identifying and
testing chromosome 3 tumor suppressor genes because of
extensive loss of heterozygosity of the 3p arm [15], and
the recent demonstration of suppression of tumorigenic-
ity in chromosome 3 fragment transfer experiments attrib-
utable to functional complementation of 3p genes [14].
The EOC cell line TOV-21G has shown no evidence of
chromosome 3 karyotypic abnormalities [2] but has dem-
onstrated evidence of microsatellite instability consistent
with mismatch repair anomalies [3].
The present study was focused on addressing the magni-
tude and extent of transcriptome modifications for differ-
ent EOC cell line models that may be influenced by tumor
microenvironment. As each cell line exhibits unique
molecular genetic characteristics comparisons of chromo-
some 3 transcriptome modifications were made with
respect to gene expression profiles generated with each
growth condition within each experimental cell line
model.
Methods
EOC cell lines
The EOC cell lines were derived from a stage III/grade 3
clear cell carcinoma (TOV-21G), a stage IIIc/grade 3
endometrioid carcinoma (TOV-112D), and from the
ascites fluid of a stage IIIc/grade 3 adenocarcinoma (OV-
90), all from chemotherapy naïve patients, as described
[2]. Cells were cultured in OSE medium consisting of
50:50 medium 199:105 (Sigma), with 2.5 μg/mL ampho-
tericin B and 50 μg/mL gentamicin [2]. Culture media was
supplemented with 10% FBS.
Source of chromosome 3 expression profiles
Chromosome 3 gene expression profiles were extracted
from normalized Affymetrix GeneChip®  HG-U133A
microarray analyses of the OV-90, TOV-21G and TOV-
112D EOC cell lines that were each grown under different
conditions as described previously [13], and will be made
available at Gene Expression Omnibus http://
www.ncbi.nlm.nih.gov/geo/. These conditions include
monolayer cultures (L), spheroid cultures (S), nude mouse
xenografts at subcutaneous (TSC) or intraperitoneal (TIP)
sites, and monolayer cultures of subcutaneous (LSC) and
intraperitoneal (LIP) xenografts, as described previously
[13]. Data normalization, which is intended to eliminate
systematic biases when comparing expression values fromBMC Medical Genomics 2008, 1:34 http://www.biomedcentral.com/1755-8794/1/34
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independently derived GeneChip®  experiments, was
achieved from the raw expression data using the MAS5
software (Affymetrix Microarray Suite®) by multiplying
the value for an individual probe set by 100 and dividing
by the mean of the raw expression values for the given
sample data set as described previously [5,10,17]. The
software also generates a reliability score for each probe
set, which reflects the level of non-specific binding. A high
reliability score of Present (P call) represents minimal
hybridization to the mismatch probe set and consistent
hybridization across all matched probes, in contrast to a
borderline score of Marginal (M call) or a score of Ambig-
uous (A call).
The normalized data set was then used to extract the
expression profiles associated with probe sets representing
chromosome 3 genes. Probe sets corresponding to chro-
mosome 3 genes were identified using the Affymetrix
NetAffx Batch Query tool http://affymetrix.com/analysis/
index.affx and the UniGene Homo sapiens database, based
on UniGene Build 198 http://www.ncbi.nlm.nih.gov/
UniGene/. Additional mapping information was
obtained from the University of California Santa Cruz
(UCSC) Human Genome Browser database, March 2006
(NCBI Build 36.1) hg 18 assembly http://
genome.ucsc.edu. Based on these databases, 1147 probe
sets were identified that mapped to chromosome 3, repre-
senting 735 genes and ESTs. Chromosome 3 alignment of
probe sets (represented genes) was determined based on
the UCSC Human Genome Browser database, where 535
probe sets mapped to genes on the chromosome 3p arm
and 612 probe sets mapped to genes on the chromosome
3q arm.
The normalized expression data sets were also rescaled to
eliminate systematic biases due to low expression values.
Low values with A-calls are considered to be technical
noise, which may influence fold-difference comparisons
and overestimate expression differences that result from
high variability of low expression values. Probe sets con-
taining A-calls may also reflect either absent expression or
poorly designed probe sets [5]. To reduce this technical
noise, values below 15 were reassigned a threshold value
of 15, based on the mean expression value of data with
low reliability scores of the chromosome 3 extracted
probe set data.
Hierarchical Cluster Analysis
Hierarchical cluster analysis was performed on normal-
ized and rescaled gene expression data analyzed using
Bioconductor, an open-source software library for the
analyses of genomic data [18] based on R, a language and
environment for statistical computing and graphics http:/
/www.r-project.org. In order to determine the significance
of the differential expression, modified t-tests were per-
formed with Bioconductor's limma package, where p-val-
ues from the resulting comparison were adjusted for
multiple testing as described [19]. This method controls
for the false discovery rate, which was set to 0.05. Biocon-
ductor's genefilter package was used to filter out probe sets
with insufficient variation in gene expression across all
tested samples for the analysis of each EOC cell line data
set. In the remaining expression values, a log base 2 scale
of at least 0.5 for the interquartile range was required
across all tested samples for each EOC cell line group as
described. Hierarchical clustering analysis was performed
with R's cluster package, using the Pearson correlation dis-
tance.
Two-way comparative analyses
Two-way comparative analyses based on fold differences
of expression values were performed on normalized and
rescaled gene expression data derived from each EOC cell
line. The expression values with at least one high-reliabil-
ity score or P call for each EOC cell line sample set (data
containing expression values generated from each growth
condition) were evaluated in two-way comparative analy-
ses. Differentially expressed genes were defined as those
which exhibited at least a 3-fold difference in two-way
comparative analyses with expression value for monol-
ayer culture and each growth condition, or between the
maximum and minimum value of expression observed
within a set of data for each EOC cell line.
Results
Hierarchical cluster analysis
Hierarchical cluster analysis of chromosome 3 gene
expression data from each EOC cell line grown in monol-
ayer cultures (L) and alternative growth conditions such
as spheroid cultures (S), nude mouse xenografts at subcu-
taneous (TSC) or intraperitoneal (TIP) sites, and monol-
ayer cultures of subcutaneous (LSC) and intraperitoneal
(LIP) xenografts is shown in Figures 1, 2 and 3. When
looking at the major branches, the xenograft-derived
monolayer cultures (LSC and LIP) cluster with the
xenografts (TSC and TIP) themselves in the case of TOV-
21G (Figure 2) and TOV-112D (Figure 3). In contrast, OV-
90 shows two major branches separating the spheroid (S)
and xenografts (TSC and TIP) from all monolayer cultures
(L, LSC and LIP) (Figure 1). It should be noted that a com-
bined hierarchical cluster analysis of all EOC cell line data
sets also results in a similar branching pattern where each
EOC cell line clusters within its own grouping rather than
with culture condition (data not shown) and this result is
consistent with the hierarchical cluster analysis of whole
genome transcriptome of these EOC cell line propagated
in different contexts [13]. However, an overall high degree
of correlation (> 90%) in gene expression was observed
when expression values of different growth conditions
were compared within each EOC cell line group, suggest-BMC Medical Genomics 2008, 1:34 http://www.biomedcentral.com/1755-8794/1/34
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Hierarchical cluster analysis of OV-90 grown in different conditions Figure 1
Hierarchical cluster analysis of OV-90 grown in different conditions. Hierarchical clustering of normalized chromo-
some 3 gene expression data sets derived from OV-90 grown as monolayer culture (L), and the alternative growth conditions 
consisting of spheroid cultures (S), tumors derived from xenograft tumors from subcutaneous (TSC) or intraperitoneal (TIP) 
injection sites in nude mice, and monolayer cultures derived from these tumors (LSC and LIP). The analysis was carried out 
using R's cluster package with the Pearson correlation distance where the y-axis 'height' represents the 1 minus the correlation 
distance. Only part of the clustering analysis is shown which includes the distal branches where the highest degree of correla-
tion begins to deviate for each growth condition (at around 92%).BMC Medical Genomics 2008, 1:34 http://www.biomedcentral.com/1755-8794/1/34
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Hierarchical cluster analysis of TOV-21G grown in different conditions Figure 2
Hierarchical cluster analysis of TOV-21G grown in different conditions. Hierarchical clustering of normalized chro-
mosome 3 gene expression data sets derived from TOV-21G grown as monolayer culture (L), and the alternative growth con-
ditions consisting of spheroid cultures (S), tumors derived from xenograft tumors from subcutaneous (TSC) or intraperitoneal 
(TIP) injection sites in nude mice, and monolayer cultures derived from these tumors (LSC and LIP). The analysis was carried 
out using R's cluster package with the Pearson correlation distance where the y-axis 'height' represents the 1 minus the corre-
lation distance. Only part of the clustering analysis is shown which includes the distal branches where the highest degree of 
correlation begins to deviate for each growth condition (at around 93%).BMC Medical Genomics 2008, 1:34 http://www.biomedcentral.com/1755-8794/1/34
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Hierarchical cluster analysis of TOV-112D grown in different conditions Figure 3
Hierarchical cluster analysis of TOV-112D grown in different conditions. Hierarchical clustering of normalized chro-
mosome 3 gene expression data sets derived from TOV-112D grown as monolayer culture (L), and the alternative growth 
conditions consisting of spheroid cultures (S), tumors derived from xenograft tumors from subcutaneous (TSC) or intraperito-
neal (TIP) injection sites in nude mice, and monolayer cultures derived from these tumors (LSC and LIP). The analysis was car-
ried out using R's cluster package with the Pearson correlation distance where the y-axis 'height' represents the 1 minus the 
correlation distance. Only part of the clustering analysis is shown which includes the distal branches where the highest degree 
of correlation begins to deviate for each growth condition (at around 96.5%).BMC Medical Genomics 2008, 1:34 http://www.biomedcentral.com/1755-8794/1/34
Page 7 of 16
(page number not for citation purposes)
ing a limited number of chromosome 3 probe sets have
altered expression profiles due to the growth conditions.
Two-way comparisons relative to the reference monolayer 
culture
To further characterize the gene expression profiles and
identify the genes that may be influenced by the growth
conditions, we applied a two-way fold-difference compar-
ative analysis approach. As monolayer cultures are often
used in molecular genetic assays of cancer derived cell
lines, we compared gene expression values of the EOC cell
lines grown as monolayer cultures with each of the alter-
native growth conditions comprised of spheroid cultures
(S), nude mouse xenografts at subcutaneous (TSC) or
intraperitoneal (TIP) sites, and monolayer cultures of sub-
cutaneous (LSC) and intraperitoneal (LIP) xenografts. We
performed two-way comparison analysis based on fold-
differences using the expression values which contained at
least one high reliability score (or P call) per probe set for
each EOC cell line. Using this criterion, the expression val-
ues of 692 (60.3%), 739 (64.4%), and 693 (60.4%) probe
sets from the total of 1147 chromosome 3 probe sets for
OV-90, TOV-21G and TOV-112D, respectively, were eval-
uated for fold-differences (Table 1). Overall less than 15%
of the probe sets exhibited greater than 3-fold differences
in gene expression when monolayer cultures were com-
pared with that of any growth condition within each EOC
cell line group (Table 1). However, it is apparent that the
majority of differences in these comparative analyses
occurred within the 3- to 5-fold range, and progressively
fewer genes exhibit differences in expression greater than
5-fold and 10-fold (Figure 4). Notable is the strikingly few
examples of genes exhibiting at least a 3-fold difference in
gene expression in two-way comparisons of monolayer
cultures of OV-90 with monolayer cultures of tumors
derived from subcutaneous (LSC) or intraperitoneal (LIP)
injection sites (Figure 4). This data is consistent with the
hierarchical cluster analysis of OV-90 normalized chro-
mosome 3 gene expression data (Figure 1). The fewest dif-
ferences overall (at 6.6%) were observed in all two-way
comparisons of the TOV-112D monolayer culture and
any of the alternate growth conditions (Table 1). These
results are also consistent with the hierarchical cluster
analysis of TOV-112D normalized chromosome 3 gene
expression data where overall this EOC cell line exhibited
the highest degree of similarity of gene expression
(~96.5%) as compared with OV-90 (~92%) (Figure 1)
and TOV-21G (92.5%) (Figure 2).
Two-way comparative analysis of the range of gene 
expression
To further characterize the differences in the gene expres-
sion patterns, we examined the range (maximum and
minimum) of the expression values exhibited by all alter-
native growth conditions. Two-way comparative analysis
was performed between the maximum and minimum val-
ues of expression observed for probe sets for each EOC
cell line group. A minimum 3-fold cut-off was used to
characterize differences in gene expression. Overall less
than 23% of probe sets exhibited greater than 3-fold dif-
ferences in gene expression in this comparative analysis in
any EOC cell line group (Table 2). It is apparent in this
analysis that the majority of differences between the max-
imum and minimum values of gene expression occurred
within the 3- to 5-fold range, and progressively fewer
genes exhibit differences in the range greater than 5- to 10-
fold or greater than 10-fold. These observations are evi-
dent when gene expression values for probe sets exhibit-
ing at least a 3-fold difference in the range of expression
for any growth condition are shown graphically as in Fig-
ures 5 to 10. For example only 10 of 122 (8%) probe sets
representing eight genes, FLNB on the 3p arm (Figure 5)
and UPK1B, H1FX, CLDN18, AGTR1, EIF4G1, SERPINI1,
and LEPREL1 on the 3q arm (Figure 6), exhibited greater
than 10-fold differences in gene expression in the analysis
of OV-90.
There were 17 genes which were found differentially
expressed greater than 3-fold in all EOC cell lines (Addi-
tional file 1). These genes may represent those that could
be affected by growth condition or tumor microenviron-
ment [13]. Notable is that the patterns of expression of
these 17 genes were not necessarily the same for each
growth condition when one cell line is compared with
another. For example in OV-90, the maximum value of
expression of RIS1 was found with the monolayer culture
(L) and both subcutaneous (TSC) and intraperitoneal
(TIP) xenografts exhibited the lowest values of expression
of this gene (Figure 5), whereas the highest level of expres-
sion of RIS1 in TOV-112D was found with the subcutane-
ous (TSC) xenograft sample and the lowest value was
observed with intraperitoneal (TIP) xenograft (Figure 9).
Discussion
In this study, we described chromosome 3 transcriptome
changes for three well characterized EOC cell lines (OV-
90, TOV-112D, and TOV-21G) that each responded dif-
ferently in relation to various growth conditions such as in
three dimensional spheroid culture and nude mouse
xenograft models, relative to the conventional monolayer
culture. However, the alternative in vitro and  in vivo
growth conditions of tumorigenic EOC cell lines appeared
to have modestly influenced the expression of chromo-
some 3 genes. This was reflected in the hierarchical cluster
analysis where there was an overall high degree of correla-
tion (> 90%) in gene expression in each EOC cell line
group tested irrespective of growth condition. It was also
reflected in the two-way comparative analyses where a 3-
fold cut-off was applied. Although we have previously
shown that replicates of Affymetrix GeneChip® expressionBMC Medical Genomics 2008, 1:34 http://www.biomedcentral.com/1755-8794/1/34
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Differential pattern of gene expression of EOC cell lines grown in different conditions Figure 4
Differential pattern of gene expression of EOC cell lines grown in different conditions. The number of differentially 
expressed genes greater than 3-fold, 5-fold or 10-fold for each alternative growth conditions (spheroid cultures (S), xenograft 
tumors derived from subcutaneous (TSC) or intraperitoneal (TIP) injection sites in nude mice, and monolayer cultures derived 
from these tumors (LSC and LIP) relative the monolayer cultures for each EOC cell line (OV-90, TOV-21G and TOV-112D) is 
shown. The lighter and darker bars represent probe sets that map to the chromosome the 3p and 3q arms, respectively.
Table 1: Two-way comparisons of gene expression values of any alternative growth condition compared with the monolayer cultures.
EOC cell line Chromosomal location of probe sets Number of probe sets analyzed Number (%) of probe sets exhibiting > 3-fold differences 
in gene expression values in two-way comparisons
OV-90 3p 294 18 (6.1)
OV-90 3q 398 56 (14.1)
OV-90 3 692 74 (10.7)
TOV-21G 3p 339 34 (10.0)
TOV-21G 3q 400 72 (18.0)
TOV-21G 3 739 106 (14.3)
TOV-112D 3p 328 15 (4.6)
TOV-112D 3q 365 31 (8.5)
TOV-112D 3 693 46 (6.6)BMC Medical Genomics 2008, 1:34 http://www.biomedcentral.com/1755-8794/1/34
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data derived from the EOC cell lines grown as monolayer
cultures were highly reproducible [5,6], a lower cut-off
(such as a 2-fold cut-off) would have captured differences
in gene expression attributable to experimental variability
[5,17]. Unlike earlier studies using Affymetrix GeneChip®
expression microarrays of the EOC cell lines, we have used
a lower threshold level of 15 rather than 50 or 100
depending on the GeneChip® used [5,6,8-10]. A lower
threshold value would increase the number of differen-
tially expressed genes occurring in the low range of gene
expression and this perhaps explains the large number of
differentially expressed genes with values falling below
150 for all growth conditions (see Figures 5 to 10). The
two-way comparison analyses were consistent with hierar-
chical cluster analyses which indicated a high correlation
in gene expression patterns in the EOC cell line regardless
Range of expression of differentially expressed 3p genes for OV-90 Figure 5
Range of expression of differentially expressed 3p genes for OV-90. The expression values of all of the growth condi-
tions are shown for genes exhibiting greater than 3-fold differences in gene expression between the monolayer cultures and 
any alternative growth condition for OV-90; and greater than 3-fold differences between the maximum and minimum value of 
expression determined for any growth condition for OV-90. The growth conditions are abbreviated as follows: monolayer cul-
ture (L), and alternative growth conditions consisting of spheroid cultures (S), xenograft tumors derived from subcutaneous 
(TSC) or intraperitoneal (TIP) injection sites in nude mice, and monolayer cultures derived from these tumors (LSC and LIP). 
For comparative purposes the expression values of the monolayer cultures are linked with a line. The gene name and probe set 
number are indicated, and are ordered (not to scale) based on the Human Genome Browser March 2006 (hg 18) assembly 
(UCSC Genome Bioinformatics database). The expression profiles are organized relative to the position of the probe sets 
(genes) for the 3ptel – 3pcen chromosome arm. The arrows indicate the genes exhibiting differential expression greater than 
3-fold in any comparative analyses that were found in common with all three EOC cell lines.BMC Medical Genomics 2008, 1:34 http://www.biomedcentral.com/1755-8794/1/34
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of growth condition. Our results with chromosome 3
genes were consistent with whole genome transcriptome
analyses of the EOC cell lines which also showed a high
correlation (> 85%) of gene expression regardless of
growth condition suggesting that microenvironment
modestly influenced gene expression [13].
The EOC cell line lines exhibited unique patterns of gene
expression as shown by the hierarchical cluster analysis.
These unique differences are also reflected in a previous
global analyses of gene expression from the entire Affyme-
trix U133A microarray [13]. Thus while gene expression
profiles of OV-90 cell line grown as tumors or spheroid
clustered together, which may indicate that gene expres-
sion patterns could be associated with growth as 3D struc-
Range of expression of differentially expressed 3q genes for OV-90 Figure 6
Range of expression of differentially expressed 3q genes for OV-90. The expression values of all of the growth condi-
tions are shown for genes exhibiting greater than 3-fold differences in gene expression between the monolayer cultures and 
any alternative growth condition of OV-90; and greater than 3-fold differences between the maximum and minimum value of 
expression determined for any growth condition for each OV-90. The growth conditions are abbreviated as follows: monol-
ayer culture (L), and alternative growth conditions consisting of spheroid cultures (S), xenograft tumors derived from subcuta-
neous (TSC) or intraperitoneal (TIP) injection sites in nude mice, and monolayer cultures derived from these tumors (LSC and 
LIP). For comparative purposes the expression values of the monolayer cultures are linked with a line. The gene name and 
probe set number are indicated, and are ordered (not to scale) based on the Human Genome Browser March 2006 (hg 18) 
assembly (UCSC Genome Bioinformatics database). The expression profiles are organized relative to the position of the probe 
sets (genes) for the 3qcen – 3qtel chromosome arm. The arrows indicate the genes exhibiting differential expression greater 
than 3-fold in any comparative analyses that were found in common with all three EOC cell lines.BMC Medical Genomics 2008, 1:34 http://www.biomedcentral.com/1755-8794/1/34
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tures, this was not the case in chromosome 3
transcriptome profiles for TOV-21G and TOV-112D. The
differences in the clustering patterns and differentially
expressed genes observed in the three EOC cell lines was
not surprising. The EOC cell lines were derived from long-
term passages of tumor tissues representing different his-
topathological subtypes of ovarian cancer [2]. These EOC
cell lines also differ in their molecular genetic characteris-
tics, in that OV-90 and TOV-112D harbor somatic muta-
tions in TP53, whereas TOV-21G harbors a somatic
mutation in KRAS and exhibits microsatellite instability.
OV-90 also is monoallelic for the 3p arm, however this
gross genomic anomaly did not significantly impact on
global patterns of gene expression of the chromosome 3p
arm as assayed by Affymetrix expression analyses of this
cell line and the other EOC cell line used in the present
Range of expression of differentially expressed 3p genes for TOV-21G Figure 7
Range of expression of differentially expressed 3p genes for TOV-21G. The expression values of all of the growth 
conditions are shown for genes exhibiting greater than 3-fold differences in gene expression between the monolayer cultures 
and any alternative growth condition of TOV-21G; and greater than 3-fold differences between the maximum and minimum 
value of expression determined for any growth condition for TOV-21G. The growth conditions are abbreviated as follows: 
monolayer culture (L), and alternative growth conditions consisting of spheroid cultures (S), xenograft tumors derived from 
subcutaneous (TSC) or intraperitoneal (TIP) injection sites in nude mice, and monolayer cultures derived from these tumors 
(LSC and LIP). For comparative purposes the expression values of the monolayer cultures are linked with a line. The gene 
name and probe set number are indicated, and are ordered (not to scale) based on the Human Genome Browser March 2006 
(hg 18) assembly (UCSC Genome Bioinformatics database). The expression profiles are organized relative to the position of 
the probe sets (genes) for the 3ptel – 3pcen chromosome arm for TOV-21G. The arrows indicate the genes exhibiting differ-
ential expression greater than 3-fold in any comparative analyses that were found in common with all three EOC cell lines.BMC Medical Genomics 2008, 1:34 http://www.biomedcentral.com/1755-8794/1/34
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study [3,8,15]. The EOC cell lines also differ in their
response to ionizing radiation and chemotherapeutic
agents [3]. Thus the unique patterns of gene expression as
shown in Figures 5 to 10 could in part reflect molecular
genetic differences of the these cell lines.
Given the molecular genetic differences in the EOC cell
lines, it is not surprising that there were few similarly dif-
ferentially expressed genes found in common with all of
EOC cell lines. Indeed there were only 17 genes in com-
mon in all three EOC cell lines which exhibited differen-
tial expression greater than 3-fold in all comparative
analyses (Additional file 1). A review of gene ontology
Range of expression of differentially expressed 3q genes for TOV-21G Figure 8
Range of expression of differentially expressed 3q genes for TOV-21G. The expression values of all of the growth 
conditions are shown for genes exhibiting greater than 3-fold differences in gene expression between the monolayer cultures 
and any alternative growth condition of TOV-21G; and greater than 3-fold differences between the maximum and minimum 
value of expression determined for any growth condition for TOV-21G. The growth conditions are abbreviated as follows: 
monolayer culture (L), and alternative growth conditions consisting of spheroid cultures (S), xenograft tumors derived from 
subcutaneous (TSC) or intraperitoneal (TIP) injection sites in nude mice, and monolayer cultures derived from these tumors 
(LSC and LIP). For comparative purposes the expression values of the monolayer cultures are linked with a line. The gene 
name and probe set number are indicated, and are ordered (not to scale) based on the Human Genome Browser March 2006 
(hg 18) assembly (UCSC Genome Bioinformatics database). The expression profiles are organized relative to the position of 
the probe sets (genes) for the 3qcen – 3qtel chromosome arm TOV-21G. The arrows indicate the genes exhibiting differential 
expression greater than 3-fold in any comparative analyses that were found in common with all three EOC cell lines.BMC Medical Genomics 2008, 1:34 http://www.biomedcentral.com/1755-8794/1/34
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suggests that some examples of the differentially
expressed genes have been associated with cellular shape
(ARPC4 and NCK1), cell growth and division (CDC25A
and SKIL), and extracellular signaling/cell-cell junctions
(ROBO1, SKIL, TM4SF1 and WNT5A) (Additional file 1).
Some of these genes have recently been identified as dif-
ferentially expressed in ovarian cancer samples relative to
normal tissue. For example, TMEM158, HEG1, PLOD2
and  ATP13A3, were recently found differentially
expressed greater than 3-fold in a comparative analysis of
primary cultures of normal ovarian surface epithelial cells
and malignant serous ovarian tumors [7]. However, the
17 differentially expressed genes observed in common
with all three EOC cell lines do not necessarily exhibit that
the same differences in gene expression patterns relative
to monolayer cultures, suggesting that they each may have
Range of expression of differentially expressed 3p genes for TOV-112D Figure 9
Range of expression of differentially expressed 3p genes for TOV-112D. The expression values of all of the growth 
conditions are shown for genes exhibiting greater than 3-fold differences in gene expression between the monolayer cultures 
and any alternative growth condition for TOV-112D; and greater than 3-fold differences between the maximum and minimum 
value of expression determined for any growth condition for TOV-112D. The growth conditions are abbreviated as follows: 
monolayer culture (L), and alternative growth conditions consisting of spheroid cultures (S), xenograft tumors derived from 
subcutaneous (TSC) or intraperitoneal (TIP) injection sites in nude mice, and monolayer cultures derived from these tumors 
(LSC and LIP). For comparative purposes the expression values of the monolayer cultures are linked with a line. The gene 
name and probe set number are indicated, and are ordered (not to scale) based on the Human Genome Browser March 2006 
(hg 18) assembly (UCSC Genome Bioinformatics database). The expression profiles are organized relative to the position of 
the probe sets (genes) for the 3ptel – 3pcen chromosome arm for TOV-112D. The arrows indicate the genes exhibiting differ-
ential expression greater than 3-fold in any comparative analyses that were found in common with all three EOC cell lines.BMC Medical Genomics 2008, 1:34 http://www.biomedcentral.com/1755-8794/1/34
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responded differently to alternative growth conditions.
Further analysis is required to determine if these 17 genes
are indeed responding to differences in microenviron-
ment as consequence of growth alternative growth condi-
tions.
Future experiments are required to determine if the differ-
ences observed in the EOC cell lines grown in alternative
conditions are biologically relevant or a reflection of
experimental design. The magnitude of the differences in
gene expression observed in the EOC cell lines grown
under the various in vitro and in vivo growth conditions
may all still be significantly different when each is com-
pared with normal cells [7]. The EOC cell lines, with their
capacity to grow in different contexts, provides an oppor-
tunity to further examine the biological relevance of tran-
Range of expression of differentially expressed 3q genes for TOV-112D Figure 10
Range of expression of differentially expressed 3q genes for TOV-112D. The expression values of all of the growth 
conditions are shown for genes exhibiting greater than 3-fold differences in gene expression between the monolayer cultures 
and any alternative growth condition for TOV112D; and greater than 3-fold differences between the maximum and minimum 
value of expression determined for any growth condition for TOV-112D. The growth conditions are abbreviated as follows: 
monolayer culture (L), and alternative growth conditions consisting of spheroid cultures (S), xenograft tumors derived from 
subcutaneous (TSC) or intraperitoneal (TIP) injection sites in nude mice, and monolayer cultures derived from these tumors 
(LSC and LIP). For comparative purposes the expression values of the monolayer cultures are linked with a line. The gene 
name and probe set number are indicated, and are ordered (not to scale) based on the Human Genome Browser March 2006 
(hg 18) assembly (UCSC Genome Bioinformatics database). The expression profiles are organized relative to the position of 
the probe sets (genes) for the 3qcen – 3qtel chromosome arm for TOV-112D. The arrows indicate the genes exhibiting differ-
ential expression greater than 3-fold in any comparative analyses that were found in common with all three EOC cell lines.BMC Medical Genomics 2008, 1:34 http://www.biomedcentral.com/1755-8794/1/34
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scriptional differences that may be influenced by the
microenvironment wherein which they are propagated.
Recently our group has applied such a strategy to specifi-
cally identify genes transcriptionally modified based on
microenvironment, and one such gene, S100A6, was
found differentially expressed relative to culture condi-
tions and further validated by RT-PCR and immunohisto-
chemistry [13]. While this finding may be disconcerting
and discourage the use of in vitro model systems for stud-
ying gene candidates, our results in the present study
show that a high correlation of gene expression in the
transcriptomes generated from ovarian cancer cell lines
propagated in different contexts. Overall these results
attests to the validity of the EOC cell lines as an in vitro
model for studying gene candidates but point out that
some genes may be influenced by microenvironment, a
factor that should be taken into consideration when
investigating the molecular biology of specific genes. As
our EOC cell lines are amenable to propagation in alter-
native growth conditions one could assay and further
investigate the magnitude of transcriptional effects for
specific candidate genes of interest and their conse-
quences at the protein level to further understand the bio-
logical relevance gene expression differences associated
with microenvironment.
Conclusion
The ability to culture tumorigenic EOC cells under differ-
ent  in vivo and  in vitro growth conditions affords the
opportunity to study gene expression of candidates in
contexts that more closely mimic tumor growth in vitro.
However, the analyses of chromosome 3 transcriptomes
are highly comparable within each EOC cell line context.
These observations would argue that gene expression
studies using monolayer cultures of ovarian cancer lines is
still a viable option for initial studies involving the char-
acterization of gene expression pattern of candidate genes.
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